Overview

Lysosomal acid lipase deficiency (LAL-D) is a rare, inherited disorder that affects the body’s ability to produce the enzyme lysosomal acid lipase (LAL), which is essential for breaking down fats (lipids) and cholesterol in cells. Without enough of this enzyme, fatty material and “bad cholesterol” (LDL) build up in organs such as the liver, spleen, and blood vessels. Over time, this buildup can lead to progressive liver disease and an increased risk of cardiovascular complications like heart attack and stroke.

LAL-D is an autosomal recessive condition, meaning a patient must inherit a defective gene from both parents to be affected. Although it can occur in people of any age, symptoms often begin in early childhood, and severe cases in infants can progress rapidly and become life-threatening within the first months of life. In children and adults, the disease may go unrecognized for years due to mild or absent symptoms, even as damage continues.

The condition commonly affects the liver, cardiovascular system, spleen, and digestive system. It can lead to complications such as liver enlargement, fibrosis, cirrhosis, liver failure, abnormal cholesterol levels, and poor nutrient absorption. Because its symptoms can resemble more common liver diseases, especially steatotic (fatty) liver diseases (MASLD and MASH), diagnosis is often delayed and typically requires a blood test to measure LAL enzyme activity.

Treatment options were historically limited to supportive care, but enzyme replacement therapy is now available to address the underlying cause of the disease and improve clinical outcomes.

Facts at-a-Glance

LAL-D is a rare genetic disorder that causes buildup of fats and cholesterol in cells, leading to liver disease and cardiovascular risk.
It is inherited in an autosomal recessive pattern, with a 25% chance that a child will be affected when both parents are carriers.
The disease can affect multiple organs, especially the liver, spleen, and blood vessels.
Symptoms often appear early in life in severe cases but may be mild or unnoticed in some individuals until later in life, as organ injury increases.
Enzyme replacement therapy is available to treat the underlying cause of LAL-D.

Symptoms and Causes

Lysosomal acid lipase deficiency (LAL-D) is caused by mutations in the LIPA gene, which result in little to no activity of the lysosomal acid lipase (LAL) enzyme. This condition is inherited in an autosomal recessive pattern, meaning an individual must inherit a defective gene from both parents to be affected. The lack of functional LAL enzyme leads to the buildup of fats and cholesterol in cells, contributing to progressive damage in multiple organs.

Symptoms of LAL-D can vary widely depending on age and disease severity. Infants typically experience rapid disease progression with symptoms such as poor growth, hepatomegaly, gastrointestinal issues, and jaundice. In children and adults, symptoms may be subtle or absent early on, which can delay diagnosis. When present, signs may include liver enlargement, abnormal cholesterol levels, and elevated liver enzymes. As the disease advances, individuals may develop complications such as liver scarring (fibrosis), fluid accumulation in the abdomen, and an increased risk of early cardiovascular events.

Diagnosis and Tests

Diagnosing Lysosomal Acid Lipase Deficiency (LAL-D) can be challenging because many of its signs and symptoms resemble more common liver and metabolic conditions. In some cases, individuals may appear healthy or have only mild symptoms in the early stages, which can delay diagnosis.

The initial step for diagnosing LAL-D is a blood test that measures the activity of the LAL enzyme. Individuals with LAL-D will have little to no enzyme activity, confirming the condition. This test is simple and is typically the first step when LAL-D is suspected.

Additional testing may be used to support the diagnosis and assess the extent of the disease. Genetic testing can identify abnormalities in the LIPA gene, helping confirm the diagnosis and determine whether other family members may be carriers. A liver biopsy may also be performed to evaluate the degree of liver damage, such as fibrosis or cirrhosis. However, a biopsy alone cannot diagnose LAL-D, since similar liver damage can occur in other conditions.

Because LAL-D shares features with more common diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), it may be overlooked or misdiagnosed. For this reason, healthcare providers should consider LAL-D in patients with unexplained liver abnormalities, abnormal cholesterol levels, or a family history of the condition.

Early and accurate diagnosis is essential, as it allows for timely treatment that can help prevent or slow disease progression and reduce the risk of serious complications.

Management and Treatment

Management of lysosomal acid lipase deficiency (LAL-D) focuses on addressing the underlying enzyme deficiency, slowing disease progression, and managing complications that may affect the liver, cardiovascular system, and other organs. Because LAL-D is a chronic condition, care typically involves long-term treatment and regular monitoring by a healthcare team.

Enzyme Replacement Therapy (ERT)

Enzyme replacement therapy with Kanuma® (sebelipase alfa) is the primary treatment for LAL-D. This therapy replaces the deficient lysosomal acid lipase (LAL) enzyme, helping the body break down fats and cholesterol more effectively. It is administered intravenously and requires ongoing treatment and monitoring. ERT has been shown to improve liver function and cholesterol levels and reduce fat accumulation in organs.

Supportive Therapies

Supportive treatments may be used alongside enzyme replacement therapy to help manage symptoms and complications, although they do not treat the underlying cause of the disease.

Lipid-lowering medications: Medications such as statins may help improve cholesterol levels but may not fully normalize them.
Dietary management: A balanced, heart-healthy diet may support overall health and cholesterol control, but it is not sufficient as a standalone treatment.
Nutritional support: May be necessary for individuals with poor growth or nutrient absorption issues.
Monitoring and symptom management: Ongoing care to address liver disease, gastrointestinal symptoms, and other complications as they arise.

Advanced Interventions

In more severe cases, additional interventions may be considered:

Liver transplantation: May be required in individuals with advanced liver disease or liver failure, though it does not cure the underlying condition.
Stem cell transplantation: Has been explored in some cases but carries significant risks and is not commonly used.

Ongoing Monitoring and Care

Regular follow-up is essential to track disease progression and response to treatment. This may include routine blood tests to assess liver function and cholesterol levels, as well as imaging or other evaluations as needed.

Early diagnosis and appropriate treatment are important for improving outcomes. With consistent care and monitoring, individuals with LAL-D can better manage the condition and reduce the risk of serious complications.

Outlook and Prognosis

The outlook for individuals with lysosomal acid lipase deficiency varies depending on the age of onset and severity of the disease. Infants with severe LAL-D often experience rapid disease progression and life-threatening complications within the first months of life. In children and adults, the disease may progress more slowly, and some individuals may remain asymptomatic for years, making early diagnosis challenging.

With the advent of enzyme replacement therapy using Kanuma® (sebelipase alfa), long-term outcomes have improved. Treatment can slow or prevent the accumulation of fats in organs, reduce liver damage, improve cholesterol levels, and decrease the risk of cardiovascular complications. Without treatment, progressive liver disease and early cardiovascular events are common, and organ damage can be severe. Lifelong monitoring and ongoing therapy are typically required to manage the disease and improve quality of life.

Prevention

Lysosomal Acid Lipase Deficiency is a genetic, inherited condition, which means it cannot be prevented through lifestyle changes or environmental factors. The disease occurs when a child inherits two abnormal copies of the LIPA gene, one from each parent, resulting in little to no activity of the LAL enzyme.

Although prevention is not possible, understanding genetic risk can play an important role in family planning. Individuals with a known family history of LAL-D may benefit from genetic counseling to better understand their likelihood of being a carrier and the potential risk of passing the condition on to their children. When both parents are carriers, there is a 25% chance with each pregnancy that their child will have LAL-D.

Early identification of the condition is key. Timely diagnosis can help ensure that treatment begins as soon as possible. In some cases, genetic testing may also be recommended for family members to identify carriers or affected individuals.

While LAL-D cannot be prevented, early treatment can help reduce the risk of serious complications, including liver disease and cardiovascular issues. Ongoing medical care and regular monitoring of liver function and cholesterol levels are essential to managing the condition and improving long-term outcomes.

Living with Lysosomal Acid Lipase Deficiency

Living with Lysosomal Acid Lipase Deficiency (LAL-D) involves ongoing care and management, but with early diagnosis and appropriate treatment, many individuals can lead active and fulfilling lives. Because LAL-D is a chronic and progressive condition, long-term monitoring and a strong partnership with a healthcare team are essential.

Diet and lifestyle can also support overall health, although they do not replace medical therapy. A balanced, heart-healthy diet may help manage cholesterol levels, and healthcare providers may recommend specific nutritional guidance based on individual needs. Staying physically active and maintaining regular medical care can contribute to better long-term outcomes.

The impact of LAL-D can vary widely from person to person. Some individuals may have few noticeable symptoms, while others may experience complications affecting the liver, cardiovascular system, or digestive health. Understanding the condition and recognizing potential symptoms, such as fatigue, abdominal discomfort, or signs of liver disease, can help individuals seek timely medical attention.

Emotional and social support are also important aspects of living with LAL-D. Connecting with patient communities, support groups, or advocacy organizations can provide valuable resources, education, and a sense of community for both patients and families navigating the condition.

Although living with LAL-D presents challenges, advances in treatment and increased awareness are improving outcomes. With proper care, monitoring, and support, individuals with LAL-D can better manage their condition and maintain their quality of life.

Patient Bill of Rights

As a patient living with a rare liver disease, you have several rights that can empower you throughout your health journey. Although every patient’s diagnosis and treatment plan are different, these rights can help you develop better working relationships with the members of your health care team and determine the best path forward for you. View ALF’s Patient Bill of Rights

Support Groups

Living with Lysosomal Acid Lipase Deficiency can feel frightening and overwhelming. Patients and caregivers may benefit from participating in support groups where they can share experiences, learn from others, and receive emotional support.

American Liver Foundation offers virtual (live) support groups for patients, transplant recipients, and caregivers as well as Facebook support groups. Click here to learn more and connect.

Search for a Clinical Trial

Clinical trials are research studies that test how well new medical approaches work in people. Before experimental treatments can be tested on human subjects in a clinical trial, it must have shown benefit in laboratory testing or animal research studies. The most promising treatments are then moved into clinical trials, with the goal of identifying new ways to safely and effectively prevent, screen for, diagnose or treat a disease.

Speak with your doctor about the ongoing progress and results of these trials to get the most up-to-date information on new treatments. Participating in a clinical trial is a great way to contribute to curing, preventing, and treating liver disease and its complications

Medically reviewed on April 2026.

Last updated on April 17th, 2026 at 10:31 am